VistaGen Therapeutics’ (NASDAQ: VTGN) New Generation Phase 3 Drug Candidate for Social Anxiety Disorder Gains Importance Amid FDA Wariness of Benzodiazepines
VistaGen has three innovative CNS drug candidates which target a wide range of anxiety, depression and neurological disorders PH94B, the Company’s most advanced drug candidate, is entering Phase 3 development for acute, on-demand treatment of social anxiety disorder Company sees potential to displace benzodiazepines currently being used to treat multiple anxiety disorders Strategy has gained in importance after U.S. FDA announced in late-September its update requirement for boxed warnings on all benzodiazepines to highlight risks of abuse, misuse, addiction, and physical dependence Benzodiazepine epidemic is as worrisome as the opioid epidemic – 92 million benzodiazepine prescriptions in 2019 according to…